ACS
NVO

Archford Capital Strategies’s Novo Nordisk NVO Stock Holding History

Archford Capital Strategies’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
+5,358
New +$230K 0.03% 323
2026
Q1 		– Sell
-5,223
Closed -$266K – 367
2025
Q4 		$266K Buy
+5,223
New +$267K 0.03% 293
2017
Q2 		– Sell
-34
Closed -$1K – 480
2017
Q1 		$1K Hold
34
– – ﹤0.01% 657
2016
Q4 		$0 Sell
34
-62
-65% -$1.12K ﹤0.01% 714
2016
Q3 		$1K Buy
96
+28
+41% +$694 ﹤0.01% 603
2016
Q2 		$2K Buy
+68
New +$1.86K ﹤0.01% 592
2016
Q1 		– Sell
-68
Closed -$2K – 454
2015
Q4 		$2K Sell
68
-24
-26% -$664 ﹤0.01% 704
2015
Q3 		$2K Buy
92
+46
+100% +$1.3K ﹤0.01% 561
2015
Q2 		$1K Hold
46
– – ﹤0.01% 607
2015
Q1 		$1.23K Hold
46
– – ﹤0.01% 618
2014
Q4 		$1K Sell
46
-14
-23% -$313 ﹤0.01% 632
2014
Q3 		$1K Hold
60
– – ﹤0.01% 630
2014
Q2 		$1.39K Hold
60
– – ﹤0.01% 749
2014
Q1 		$1.37K Buy
+60
New +$1.28K ﹤0.01% 697

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Archford Capital Strategies's NVO Position: Q2 2026 in Review

Archford Capital Strategies opened a new position in Novo Nordisk (NVO) in Q2 2026: 5,358 shares worth $257K. The stake represents 0.03% of the portfolio and ranks #323 among its holdings. This is a return to the name: Archford Capital Strategies previously reported a position in NVO as recently as Q4 2025.

Archford Capital Strategies first reported a position in NVO in Q1 2014 and has held it in 14 quarters since. The position peaked at $266K in Q4 2025. 437 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Archford Capital Strategies held 5,358 shares of Novo Nordisk worth $257K as of Q2 2026.
  • Novo Nordisk was a new Archford Capital Strategies position in Q2 2026.
  • Novo Nordisk made up 0.03% of Archford Capital Strategies's portfolio in Q2 2026, its #323 holding.
  • Archford Capital Strategies first reported a position in Novo Nordisk in Q1 2014 and has held it in 14 quarters since.
  • Archford Capital Strategies's Novo Nordisk position peaked at $266K in Q4 2025.
  • 437 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Archford Capital Strategies's 13F filing for Q2 2026, filed 17 Jul 2026.